TNM-based risk eligibility for adjuvant trials in renal cell carcinoma.

Lancet (London, England). 2023 Jul 28 [Epub]

Jens Bedke, Axel Bex

Department of Urology and Transplantation Surgery, Klinikum Stuttgart-Katharinenhospital, 70174 Stuttgart, Germany; Stuttgart Cancer Center-Tumorzentrum Eva Mayr-Stihl, Stuttgart, Germany. Electronic address: ., The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.